Your FACTS are correct. There is no trouble with the SEC. I have confirmed this myself. Anything you hear otherwise is not FACT. Long and strong my friend.
As per FDA. 1) NO PMA or De-novo. 2) 510K and no human clinical studies required. 3) No cadaver study required (Preferred , but no the red flag). 4) FDA accepts imaging protocol proposal. Performance data comparison using phantom is sufficient. (Load) 5) FDA agree on predicate device selection for equivalence determination. (Load)